How big is Lisata Therapeutics, Inc.?

As of Jun 18, Lisata Therapeutics, Inc. has a market capitalization of 20.66 million, with net sales of 1.00 million and a net loss of 19.30 million over the latest four quarters. Shareholder's funds are valued at 29.57 million, and total assets amount to 35.00 million.

As of Jun 18, Lisata Therapeutics, Inc. has a market capitalization of 20.66 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1.00 million for the latest four quarters, while the net profit for the same period was a loss of 19.30 million.<BR><BR>As of Dec 24, the shareholder's funds were valued at 29.57 million, and the total assets amounted to 35.00 million.

What does Lisata Therapeutics, Inc. do?

Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing cell therapies for cardiovascular and autoimmune diseases. It has a market cap of $20.66 million and reported a net profit loss of $5 million as of March 2025.

Overview: <BR>Lisata Therapeutics, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 20.66 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -76.15% <BR>Price to Book: 0.81 <BR><BR>Contact Details: <BR>Address: 110 Allen Rd, BASKING RIDGE NJ: 07920-4500 <BR>Tel: 1 908 8420100 <BR>Website: https://www.caladrius.com/

Should I buy, sell or hold Lisata Therapeutics, Inc.?

Who are in the management team of Lisata Therapeutics, Inc.?

As of March 2022, the management team of Lisata Therapeutics, Inc. includes Dr. Gregory Brown (Independent Chairman), Dr. David Mazzo (CEO), Dr. Michael Davidson, Ms. Anne Whitaker, and independent directors Mr. Steven Klosk, Mr. Steven Myers, and Ms. Cynthia Schwalm. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Lisata Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Gregory Brown, Independent Chairman of the Board<BR>- Dr. David Mazzo, President, Chief Executive Officer, and Director<BR>- Dr. Michael Davidson, Director<BR>- Ms. Anne Whitaker, Director<BR>- Mr. Steven Klosk, Independent Director<BR>- Mr. Steven Myers, Independent Director<BR>- Ms. Cynthia Schwalm, Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Lisata Therapeutics, Inc. overvalued or undervalued?

As of February 27, 2025, Lisata Therapeutics, Inc. is rated "risky" and considered overvalued, with a year-to-date return of -19.80%, significantly underperforming the S&P 500's 2.44% return.

As of 27 February 2025, Lisata Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a Price to Book Value of 0.91, an EV to EBIT of 0.12, and an EV to EBITDA of 0.12. In comparison, Protara Therapeutics, Inc. has a valuation grade of "does not qualify" with an EV to EBITDA of 0.1010, while Cosmos Health, Inc. also carries a "risky" grade with an EV to EBITDA of -1.9265.<BR><BR>The company's recent performance has been poor, with a year-to-date return of -19.80%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. This trend reinforces the valuation assessment, indicating that Lisata Therapeutics is currently overvalued in the market.

Is Lisata Therapeutics, Inc. technically bullish or bearish?

As of September 8, 2025, Lisata Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -19.80% compared to the S&P's 12.22%.

As of 8 September 2025, the technical trend for Lisata Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly timeframes. The Bollinger Bands also indicate a mildly bearish trend on both weekly and monthly periods. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -19.80% versus the S&P 500's 12.22%, and a 3-year return of -52.20% compared to the S&P 500's 70.41%.